You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Australian regulator approves Endologix's abdominal aortic aneurysm treatment
State Of Singapore Online Video Subscription
Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition
Episode 43 - More Change, M&A On Horizon For Equity Research Industry
Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets
The Australian Therapeutic Goods Administration approved Endologix Inc.'s AFX2 Bifurcated Endograft System for inclusion on the Australian register of therapeutic goods.
The regulator has approved the use of AFX2 for the treatment of abdominal aortic aneurysms.
Endologix CEO John McDermott said the approval in Australia will allow the company to start offering the latest version of the anatomical fixation system to physicians and patients starting in 2017.